Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Russell Bakken"'
Autor:
Brett F. Beitzel, Sheli R. Radoshitzky, Nicholas Di Paola, Jennifer M. Brannan, David Kimmel, Katie Caviness, Veronica Soloveva, Shuiqing Yu, Elena N. Postnikova, Courtney L. Finch, Hu Liu, Laura Prugar, Russell Bakken, John M. Dye, Jeffrey R. Kugelman, James M. Cunningham, Mariano Sanchez-Lockhart, Jens H. Kuhn, Gustavo Palacios
Publikováno v:
Viruses, Vol 13, Iss 10, p 2010 (2021)
Biosafety, biosecurity, logistical, political, and technical considerations can delay or prevent the wide dissemination of source material containing viable virus from the geographic origin of an outbreak to laboratories involved in developing medica
Externí odkaz:
https://doaj.org/article/0ee43d4ed623440aa0b0b3157867c4e1
Autor:
Andrew S. Herbert, Cristin Davidson, Ana I. Kuehne, Russell Bakken, Stephen Z. Braigen, Kathryn E. Gunn, Sean P. Whelan, Thijn R. Brummelkamp, Nancy A. Twenhafel, Kartik Chandran, Steven U. Walkley, John M. Dye
Publikováno v:
mBio, Vol 6, Iss 3 (2015)
ABSTRACT Recent work demonstrated that the Niemann-Pick C1 (NPC1) protein is an essential entry receptor for filoviruses. While previous studies focused on filovirus entry requirements of NPC1 in vitro, its roles in filovirus replication and pathogen
Externí odkaz:
https://doaj.org/article/263ccfc6711f4321bc9f6e259ae2e4fb
Autor:
Yueh-Ming Loo, Andrew S Herbert, Ana I Kuehne, Patrick M McTamney, Richard Roque, Alicia M Moreau, Russell Bakken, Christopher P Stefan, Jeffrey W Koehler, Korey L Delp, Susan R Coyne, Christopher D Kane, John M Dye, Yingyun Cai, Mark T Esser
Publikováno v:
Open Forum Infectious Diseases. 9
Background AZD7442—a combination of 2 human, extended–half-life, SARS-CoV-2–neutralizing monoclonal antibodies (mAbs) (tixagevimab/cilgavimab)—has received US Food and Drug Administration emergency use authorization for COVID-19 prevention in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95647c7c7925fc2372f4b8160e1e5eeb
https://doi.org/10.1093/ofid/ofac492.981
https://doi.org/10.1093/ofid/ofac492.981
Autor:
Danielle Dorosky, Laura I. Prugar, Szuyan Pu, Cecilia O’Brien, Russell Bakken, Steven De Jonghe, Piet Herdewijn, Jennifer Brannan, John M. Dye, Shirit Einav
Publikováno v:
The Journal of Immunology. 200:50.7-50.7
Ebola virus (EBOV) and Marburg virus (MARV) are highly pathogenic members of the family filoviridae. The recent West Africa epidemic of Ebola virus disease was a grave reminder of the unmet need for post exposure therapeutics to combat filovirus infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dce744172645d5f7821eb0916acc08e1
https://doi.org/10.4049/jimmunol.200.supp.50.7
https://doi.org/10.4049/jimmunol.200.supp.50.7
Autor:
Laura I. Prugar, Danielle Dorosky, Frederick Holtsberg, Sergey Shulenin, Hong Vu, Katy Howell, Russell Bakken, Jennifer Brannan, John M. Dye, M. Javad Aman
Publikováno v:
The Journal of Immunology. 200:180.13-180.13
While disregarded in the past, the use of antibody therapeutics in the treatment of filovirus infection has been gaining traction in recent years. Early studies in our lab with the treatment of non-human primates (NHPs) with polyclonal antibodies fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d9b42ea5bd6140fc1d71535d1e48c61
https://doi.org/10.4049/jimmunol.200.supp.180.13
https://doi.org/10.4049/jimmunol.200.supp.180.13
Publikováno v:
The Journal of Immunology. 200:180.11-180.11
Pan-Ebolavirus neutralizing antibodies MBP087 and MBP047, derived from a human EBOV survivor, are protective in rodent models when administered therapeutically two days after infection. Mutations in the Fc region of hIgG, known as YTE and XTND, prolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07d8ceb625cb654395c89dbb1c5b57ba
https://doi.org/10.4049/jimmunol.200.supp.180.11
https://doi.org/10.4049/jimmunol.200.supp.180.11
Autor:
Samantha Zak, Ana Kuehne, James Barth, Andrew Herbert, Majidat Muhammad, Ramon Ortiz, Laura Prugar, Brian Hannah, Russell Bakken, William Pratt, John Dye
Publikováno v:
The Journal of Immunology. 188:113.1-113.1
The Venezuelan equine encephalitis replicon (VRP) is the lead candidate for development as the DoD filovirus vaccine platform. One concern regarding this vaccine candidate focuses on the need to vaccinate individuals that have been pre-exposed to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6a353d0940b32445854325fcd6bf3b7
https://doi.org/10.4049/jimmunol.188.supp.113.1
https://doi.org/10.4049/jimmunol.188.supp.113.1
Publikováno v:
The Journal of Immunology. 182:45.10-45.10
Ebola virus, a filovirus, is a highly pathogenic human pathogen for which there is no vaccine or treatments licensed for human use. The Sudan subtype of the Ebola virus (SEBOV) was first identified in 1976 after a hemorrhagic fever outbreak in that r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c836852cdfe523070997877f8eef3ce7
https://doi.org/10.4049/jimmunol.182.supp.45.10
https://doi.org/10.4049/jimmunol.182.supp.45.10